Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
✍ Scribed by Olivia Pagani; Karen N. Price; Richard D. Gelber; Monica Castiglione-Gertsch; Stig B. Holmberg; Jurij Lindtner; Beat Thürlimann; John Collins; Martin F. Fey; Alan S. Coates; Aron Goldhirsch; International Breast Cancer Study Group (IBCSG)
- Publisher
- Springer US
- Year
- 2009
- Tongue
- English
- Weight
- 206 KB
- Volume
- 117
- Category
- Article
- ISSN
- 0167-6806
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract At the time of treatment in 1977 for primary breast cancer of all stages, the tumors of 270 women were examined for estrogen‐receptor (ER) content by iso‐electric focusing on polyacrylamide gel. The procedures for the initial and follow‐up examinations were standardized. Postoperative a
## Abstract ## BACKGROUND Adjuvant aromatase inhibitors (AIs), instead of or after tamoxifen, are effective in decreasing recurrence in postmenopausal women with estrogen receptor (ER)‐positive breast cancer. An understanding of which patients are at risk of early recurrence while they are receivi
## Abstract The possible association of high soy food consumption with low incidence of breast cancer in Asian countries has been widely investigated, but findings from epidemiologic studies have been inconsistent. Breast cancers defined by receptor status, estrogen receptor (ER), progesterone rece
Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women. Estrogen receptor (ER) status in breast cancer is useful in predicting the response to the hormonal treatments. Of 134 postmenopausal metastatic breast cancer patients treat